PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• New immunotherapies targeting PD-1/PD-L1 are emerging for non-small-cell lung cancer (NSCLC).
• Patient stratification is needed to identify those likely to benefit from these treatments.
• PD-L1 expression on tumor cells may predict response to PD-1 inhibitors.

Purpose of the Study:

• To review current knowledge on PD-L1 testing for NSCLC.
• To identify research requirements for PD-L1 testing.
• To guide the use of PD-1/PD-L1 targeted therapies in NSCLC.

Main Methods:

• Review of current literature on PD-L1 testing in NSCLC.
• Analysis of key factors in PD-L1 testing: sample collection, pre-analytical steps, analytical decisions, and interpretation.
• Discussion of quality assurance and integration of PD-L1 testing into clinical practice.

Main Results:

• PD-L1 immunohistochemical staining is of considerable interest for guiding PD-1 targeted treatments.
• Key factors include sample handling, assay choice, quality assurance, and result interpretation.
• Integration with other tests and regular guideline updates are necessary.

Conclusions:

• Standardized PD-L1 testing is essential for effective NSCLC immunotherapy.
• Further research is required to address remaining uncertainties in PD-L1 testing.
• Regularly updated guidance is needed as new information becomes available.